Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Biomedical Catalyst Feasibility Award to Tackle Drug-resistant Ovarian Cancer

Published: Tuesday, September 17, 2013
Last Updated: Tuesday, September 17, 2013
Bookmark and Share
Feasibility award granted by Technology Strategy Board to identify DUBs.

MISSION Therapeutics has been granted a Biomedical Catalyst Feasibility Award by the Technology Strategy Board to support the identification of DUBs required for the survival of drug-resistant ovarian cancers.

Ovarian cancer is the fifth most common cancer in women and is responsible for more deaths per year than any other cancer of the female reproductive system.

Unfortunately, development of drug resistance remains the main limitation of current chemotherapies for ovarian cancer.

Identifying novel targets and therapies tailored for treating drug-resistant ovarian cancer is thus an area of clear unmet clinical need.

Using an innovative approach, MISSION will identify novel DUB targets by exploiting the very changes in tumours that led to the development of drug resistance.

Commenting on the announcement, Dr Niall Martin, MISSION Chief Operating Officer, said: “The decision of the Technology Strategy Board to support our work shows the potential the DUB space holds for treating cancer. The funds from this Feasibility Award will be used to screen all known DUBs to find those which are suitable targets for our drug development programmes.”

The project will see MISSION identify DUB targets whose inhibition selectively kills drug-resistant ovarian tumours or re-sensitizes them to chemotherapy.

The most promising targets will enter MISSION’s pipeline for further drug discovery efforts with a view to developing new therapeutic agents for ovarian cancer.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

MISSION Secures £20 million ($32 million) in Series B Financing
Pfizer Venture Investments join MISSION investor syndicate to advance compounds through preclinical development for genetically-defined cancers.
Tuesday, November 19, 2013
Appointment of Associate Faculty Member at Sanger Institute
MISSION Co-Founder and CSO, Professor Steve Jackson appointed as Faculty Member.
Monday, April 08, 2013
MISSION Therapeutics Strengthens Board
Appointments of Michael Moore and Fritz Frickel as Executive Chairman and Non-Executive Director respectively.
Monday, October 01, 2012
Scientific News
New Gene Therapy for Vision Loss From a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Predictive Model for Breast Cancer Progression
Biomedical engineers have demonstrated a proof-of-principle technique that could give women and their oncologists more personalized information to help them choose options for treating breast cancer.
Specific Variations in RNA Splicing Linked to Breast Cancer
Researchers have identified cellular changes that may play a role in converting normal breast cells into tumors. Targeting these changes could potentially lead to therapies for some forms of breast cancer.
Gene Expression: A Snapshot of Stem Cell Development
New genes found that regulate development of stem cells.
Assessing Cancer Patient Survival and Drug Sensitivity
RNA editing events another way to investigate biomarkers and therapy targets.
Editing Genes to Create HIV Killers
Seattle scientists have managed to genetically transform human cells in the lab from HIV targets to HIV killers, and the technique could have implications for cancer and other diseases.
Researchers Disguise Drugs As Platelets to Target Cancer
Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient’s own platelets.
A New Single-Molecule Tool to Observe Enzymes at Work
A team of scientists at the University of Washington and the biotechnology company Illumina have created an innovative tool to directly detect the delicate, single-molecule interactions between DNA and enzymatic proteins.
Milestone Single-Biomolecule Imaging Technique May Advance Drug Design
The first nanometer resolved image of individual tobacco mosaic virions shows the potential of low-energy electron holography for imaging biomolecules at a single particle level; a milestone in structural biology and a potential new tool for drug design.
Opening the Door to Safer, More Precise Cancer Therapies
New method regulates when, and how strongly, cancer-killing therapeutic T cells are activated.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos